Drug Trial Radar · NCT02080468
Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects
Last checked: Nov 20, 2026Latest source record: Mar 11, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Feb 19, 2014
Primary completion
Apr 24, 2014
Study completion Apr 24, 2014
Sponsor
- Lead sponsor
- Aegerion Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 6, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- Who can join
- Female only, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the effect of ethinyl estradiol (EE)/norgestimate, a weak cytochrome P450 (CYP) 3A4 inhibitor, on the pharmacokinetics (PK) of lomitapide and 2 primary metabolites, M1 and M3.
Conditions
- Healthy
Interventions
lomitapideDrug
20 mg
EE/norgestimateDrug
1x0.035-mg EE/0.25-mg norgestimate tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax for Arm 1 (Lomitapide & EE/Noregestimate - Taken Together)Time frame: 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing
- Tmax for Arm 1 (Lomitapide & EE/Noregestimate - Taken Together)Time frame: 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing
- AUC0-t for Arm 1 (Lomitapide & EE/Noregestimate - Taken Together)Time frame: 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing
- AUC0-∞ for Arm 1 (Lomitapide & EE/Noregestimate - Taken Together)Time frame: 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing
- t1/2 for Arm 1 (Lomitapide & EE/Noregestimate - Taken Together)Time frame: 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Covance Clinical Research Unit, Inc
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.